<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04664192</url>
  </required_header>
  <id_info>
    <nct_id>NCT04664192</nct_id>
  </id_info>
  <brief_title>Bio-Banking of Specimens for Advanced Lung Disease and Lung Transplant Research</brief_title>
  <official_title>Bio-Banking of Specimens for Advanced Lung Disease and Lung Transplant Research</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Baylor Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Baylor Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A major goal of this protocol is to support biomarker studies in advanced lung diseases, lung&#xD;
      transplantation care, and to improve our understanding of the effects of viral and other&#xD;
      infectious exposures to outcomes in our lung transplant and ALD patient populations.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The identification of biomarkers in a patient's blood or tissue that are specific for&#xD;
      particular medical conditions (such as interstitial lung disease, chronic obstructive lung&#xD;
      disease (COPD), and post-lung transplant rejection) is important for the prevention and early&#xD;
      detection of the disease, as well as to advance our understanding of targeted therapies.&#xD;
      Availability of biomarkers for diagnosis and for the prediction of patient prognosis and&#xD;
      therapy promises personalized medicine. Patients may be selected based on the presence of&#xD;
      particular gene mutations or circulating protein levels to receive personalized treatment.&#xD;
      Furthermore, knowledge regarding genetic risk and susceptibility to infectious diseases as&#xD;
      well as structural lung disease is rapidly growing-as whole genome sequencing and genome-wide&#xD;
      association studies have become easier to do, genetic risk has emerged as increasingly&#xD;
      important in understanding why and how some patients develop chronic lung disease. This is&#xD;
      true for the spectrum of lung diseases treated in the ALD program, from those with airways&#xD;
      diseases such as COPD to diffuse parenchymal lung diseases such as idiopathic pulmonary&#xD;
      fibrosis (IPF). The availability of human biological specimens for research purposes is&#xD;
      crucial for the advancement of medical knowledge of understanding, diagnosing, and treating&#xD;
      chronic lung diseases and optimizing post-lung transplant care.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 4, 2021</start_date>
  <completion_date type="Anticipated">December 1, 2026</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2025</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Diagnosis of patients with lung transplant</measure>
    <time_frame>5 years</time_frame>
    <description>ICD 10 code for underlying lung disease</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Survival</measure>
    <time_frame>5 years</time_frame>
    <description>Date of death</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Respiratory Failure</condition>
  <condition>Interstitial Lung Disease</condition>
  <condition>Lung Diseases</condition>
  <arm_group>
    <arm_group_label>Lung transplant Recipients</arm_group_label>
    <description>Biobank registry for Lung transplant recipients</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Patient Biospecimen Registry (observational and blood sampling)</intervention_name>
    <description>Clinical data collected at every blood sample collection visit.</description>
    <arm_group_label>Lung transplant Recipients</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood samples, serum samples, plasma samples&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Lung transplant recipients&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. All individuals aged 18 years and older&#xD;
&#xD;
          2. Persons who have undergone lung transplantation at Baylor University Medical Center in&#xD;
             the previous 10 years&#xD;
&#xD;
          3. Individual is able to understand and sign the informed consent form&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Significant documented anemia (hemoglobin &lt;8 g/dL)&#xD;
&#xD;
          2. Blood transfusions within past 3 weeks&#xD;
&#xD;
          3. Active cancer (non-skin cancers)&#xD;
&#xD;
          4. Enrollment against doctor recommendation&#xD;
&#xD;
          5. Patient not able to provide informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Susan Mathai, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Baylor Scott &amp; White Research Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Susan Mathai, MD</last_name>
    <phone>214-820-6856</phone>
    <email>Susan.Mathai@bswhealth.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Joost Felius, PhD</last_name>
    <phone>214-820-6856</phone>
    <email>Joost.Felius@BSWHealth.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Baylor Scott &amp; White Research Institute</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amanda Doss</last_name>
      <phone>214-865-2419</phone>
      <email>AMANDA.DOSS@BSWHEALTH.ORG</email>
    </contact>
    <investigator>
      <last_name>Susan Mathai, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>December 7, 2020</study_first_submitted>
  <study_first_submitted_qc>December 7, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 11, 2020</study_first_posted>
  <last_update_submitted>July 20, 2021</last_update_submitted>
  <last_update_submitted_qc>July 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Baylor Research Institute</investigator_affiliation>
    <investigator_full_name>Susan Mathai</investigator_full_name>
    <investigator_title>Pulmonary Disease specialist</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Respiratory Insufficiency</mesh_term>
    <mesh_term>Lung Diseases, Interstitial</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

